I currently carry out high-throughput drug screens and genome-wide CRISPR-Cas9 synthetic-lethal screens in human cancer cell cultures. This work aids in identifying genetic features of cancer cells that are predictive of drug sensitivity and dependencies which have potential to be new oncology drug targets. Previously, I performed high-throughput library preparation of the SARS-CoV-2 genome to provide COVID-19 surveillance across the United Kingdom.
I am interested in science which has an impact on improving people’s health and lives, which led me to my roles at the Sanger Institute.